Namarel Ventures
VC Fund
Barcelona, Spain
Namarel Ventures is an early-stage investment firm that focuses on innovative, data-driven healthcare companies.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Namarel Ventures invests in
Stages Namarel Ventures invests in
Countries Namarel Ventures invests in
Round sizes
Round size
- Seed
- $1.1M–$4.2M
Investment Focus
Industry
- Health Care 3 (38%)
- Health Diagnostics 2 (25%)
- Artificial Intelligence 2 (25%)
- Video 1 (13%)
- Computer 1 (13%)
Stage
- Seed 3 (38%)
- Series A 2 (25%)
- Grant 1 (13%)
- Venture - Series Unknown 1 (13%)
Country
- Spain 3 (38%)
- Italy 1 (13%)
- Israel 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TeiaCare is an Italian start-up born in 2018 with the aim of transferring technology and innovation knowledge to care homes.Our first solution, Ancelia, is an AI-powered operating system designed to increase transparency in the care and assistance processes, both inside the care home and towards residents' families.TeiaCare, based inMilan, operates in Italy and Spain, has a team of 15 people and is supported by international investors. | $8.2M / Venture - Series Unknown / Apr 09, 2026 | ||
| Health Lean Analytics is a Barcelona‑based health‑tech startup that builds hospital‑operations and operating‑room analytics software, using data automation, IoT, and AI to streamline surgical workflows and improve hospital efficiency. Health Lean Analytics is a B2B hospital‑operations platform that focuses on the surgical suite and perioperativeenvironment. It automates data capture from hospital workflows so staff do not have to manually enter information, reducing errors and administrative burden. | $1.6M / Seed / Mar 18, 2026 | ||
| Magentiq Eye Ltd. was established in 2014 with the aim to harness the most cutting edge computer vision and deep learning techniques to aid doctors in endoscopic procedures. Doctors today spend hours during Endoscopic Procedures looking at the LCD screens in order to explore, examine and treat various conditions. At Magentiq Eye we put the growingpower of Deep Learning, Image and Video Processing to the help of doctors, so they can be more accurate and effective- ultimately saving millions of lives and billions of dollars. Our first product is APDS: Automatic Polyp Detection System, developed to be used in online and offline colonoscopies. Our APDS (Automatic Polyp Detection System) can point out the suspicious locations of polyps in the videos, increasing the attentiveness of doctors during procedures, thus helping them to reduce their polyp miss-rates. Given the large population that annually undergoes colonoscopy, even a modest decrease in polyp miss-rate can save a lot of lives! The APDS- RT runs on the video feed from the endoscopic camera used by the physician in real time during the endoscopic procedure (currently only on Colonoscopy Procedure). The APDS-OFL is a software that runs in off-line mode on pre-Recorded Colonoscopy Videos. It is estimated that 40 million colonoscopy procedures are performed every year (almost 40% in the US alone). The ability of colonoscopy procedures to decrease the number of colon cancer cases has been proven without a doubt and their number expected to grow. However, researches have shown that there is about 25% of misses (undetected polyps) in those procedures, misses which can, unfortunately, cause interval cancer. Within this context The APDS can be sold as an add-on to the colonoscopy system or as a service (license per exam), paid by the clinic or hospital. Once the APDS system would be formally proven, during the next year, to improve polyp detection rate, it could be sold either jointly with the endoscopic equipment providers or it can be integrated in the colonoscopy devices. | Series A / Jul 30, 2025 | ||
| Sycai Technologies provides detect pancreatic cystic lesions, diagnosis, pancreatic cysts, software mask, assure patient data protection, and disruptive radiology assistant services. | $3.1M / Series A / Jan 23, 2025 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $4.2M / Seed / Nov 27, 2023 | ||
| MiMARK specializes in developing in vitro diagnostic solutions to improve the management of gynecological malignancies. The company envisions the gynecological fluid as the next step in liquid biopsy in gynecology. MiMARK 's first objective is to improve endometrial cancer diagnosis. | $1.1M / Seed / Jun 08, 2023 | ||
| NIMBLE Diagnostics is a technological organization that develops and provides services related to biotechnology research activities. | $1.1M / Grant / Jan 15, 2023 | ||
| See all 8 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Namarel Ventures invest in?
Namarel Ventures invests primarily in Health Care, Health Diagnostics and Artificial Intelligence startups, most often at Seed and Series A stage. Most of the 8 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Namarel Ventures's check size?
Namarel Ventures typically joins rounds of $1.1M–$4.2M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Namarel Ventures participates in.
When did Namarel Ventures last invest?
The most recent investment recorded for Namarel Ventures closed in Apr 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
